Expression of heparanase and angiopoietin-2 in patients with endometriosis

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 136, Issue 2, 2008, Pages 199-209

  Jingting, Cai ^a   Yangde, Zhang ^b   Yi, Zhang ^a   Mengxiong, Li ^a   Rong, Yu ^a   Yu, Zhang ^a   Guoqing, Peng ^a   Lixiu, Peng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Angiogenesis; Angiopoietin 2; Endometriosis; Heparanase; Invasion

Indexed keywords

ANGIOPOIETIN 2; HEPARANASE; MESSENGER RNA;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIOSIS; ENDOMETRIUM; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYSTEROSCOPY; IMMUNOHISTOCHEMISTRY; LAPAROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; UTERINE TUBE LIGATION; WESTERN BLOTTING;

EID: 38849205515     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2006.09.018     Document Type: Article

References (50)

1. Starzinski-Powitz A., Handrow-Metzmacher H., and Kotzian S. The putative role of cell adhesion molecules in endometriosis: can we learn from tumour metastasis?. Mol Med Today 5 7 (1999) 304-309
2. Zeitvogel A., Baumann R., and Starzinski-Powitz A. Identification of an invasive, N-cadherin-expressing epithelial cell type in endometriosis using a new cell culture model. Am J Pathol 159 5 (2001) 1839-1852
3. Starzinski-Powitz A., Gaetje R., Zeitvogel A., et al. Tracing cellular and molecular mechanisms involved in endometriosis. Hum Reprod Update 4 5 (1998) 724-729
4. Matsuzaki S., Canis M., Pouly J.L., et al. The macrophage stimulating protein/RON system: a potential novel target for prevention and treatment of endometriosis. Mol Hum Reprod 11 5 (2005) 345-349
5. Naomoto Y., Takaoka M., Okawa T., et al. The role of heparanase in gastrointestinal cancer (Review). Oncol Rep 14 1 (2005) 3-8
6. McKenna G.J., Meneghetti A., Chen Y.L., et al. Predictive value of lymph node and tumor matrix metalloproteinase expression in the analysis of metastatic periampullary tumors. J Surg Oncol 15, 90 4 (2005) 239-246
7. Hundsdorfer B., Zeilhofer H.F., Bock K.P., et al. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity-clinical relevance and prognostic value. J Craniomaxillofac Surg 33 3 (2005) 191-196
8. Uzan C., Cortez A., Dufournet C., et al. Eutopic endometrium and peritoneal, ovarian and bowel endometriotic tissues express a different profile of matrix metalloproteinases-2, -3 and -11, and of tissue inhibitor metalloproteinases-1 and -2. Virchows Arch 445 6 (2004) 603-609
9. Shan K., Ying W., Jian-Hui Z., et al. The function of the SNP in the MMP1 and MMP3 promoter in susceptibility to endometriosis in China. Mol Hum Reprod 11 6 (2005) 423-427
10. Hudelist G., Lass H., Keckstein J., et al. Interleukin 1alpha and tissue-lytic matrix metalloproteinase-1 are elevated in ectopic endometrium of patients with endometriosis. Hum Reprod 20 6 (2005) 1695-1701
11. Huang H.F., Hong L.H., Tan Y., et al. Matrix metalloproteinase 2 is associated with changes in steroid hormones in the sera and peritoneal fluid of patients with endometriosis. Fertil Steril 81 5 (2004) 1235-1239
12. Ramon L., Gilabert-Estelles J., Castello R., et al. mRNA analysis of several components of the plasminogen activator and matrix metallo-proteinase systems in endometriosis using a real-time quantitative RT-PCR assay. Hum Reprod 20 1 (2005) 272-278
13. Lembessis P., Milingos S., Michalas S., et al. Urokinase-type plasminogen activator and insulin-like growth factor-binding protein 3 mRNA expression in endometriotic lesions and eutopic endometrium: implications for the pathophysiology of endometriosis. Ann N Y Acad Sci 997 (2003) 223-228
14. Sillem M., Prifti S., Monga B., et al. Soluble urokinase-type plasminogen activator receptor is over-expressed in uterine endometrium from women with endometriosis. Mol Hum Reprod 3 12 (1997) 1101-1105
15. Kelly T., Suva L.J., Huang Y., et al. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Res 1, 65 13 (2005) 5778-5784
16. Joyce J.A., Freeman C., Meyer-Morse N., et al. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 9, 24 25 (2005) 4037-4051
17. Roy M., Reiland J., Murry B.P., et al. Antisense-mediated suppression of heparanase gene inhibits melanoma cell invasion. Neoplasia 3 (2005) 253-262
18. Liu Y.B., Gao S.L., Chen X.P., et al. Expression and significance of heparanase and nm23-H1 in hepatocellular carcinoma. World J Gastroenterol 7, 11 9 (2005) 1378-1381
19. Ogishima T., Shiina H., Breault J.E., et al. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res 1, 11 3 (2005) 1028-1036
20. Murry B.P., Greiter-Wilke A., Paulsen D.P., et al. Selective heparanase localization in malignant melanoma. Int J Oncol 26 2 (2005) 345-352
21. Sato T., Yamaguchi A., Goi T., et al. Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis. J Surg Oncol 87 4 (2004) 174-181
22. Elkin M., Cohen I., Zcharia E., et al. Regulation of heparanase gene expression by estrogen in breast cancer. Cancer Res 15, 63 24 (2003) 8821-8826
23. Kelly T., Miao H.Q., Yang Y., et al. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res 15, 63 24 (2003) 8749-8756
24. Zhu Y., Lee C., Shen F., et al. Angiopoietin-2 facilitates vascular endothelial growth factor-induced angiogenesis in the mature mouse brain. Stroke 36 7 (2005) 1533-1537
25. Watanabe D., Suzuma K., Suzuma I., et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 139 3 (2005) 476-481
26. Emoto M., Charnock-Jones D.S., Licence D.R., et al. Localization of the VEGF and angiopoietin genes in uterine carcinosarcoma. Gynecol Oncol 95 3 (2004) 474-482
27. Oliner J., Min H., Leal J., et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6 5 (2004) 507-516
28. Mihalich A., Reina M., Mangioni S., et al. Different basic fibroblast growth factor and fibroblast growth factor-antisense expression in eutopic endometrial stromal cells derived from women with and without endometriosis. J Clin Endocrinol Metab 88 6 (2003) 2853-2859
29. Oliveira V.A., Abreu L.G., Ferriani R.A., et al. Vascular endothelial growth factor in the plasma, follicular fluid and granulosa cells of women with endometriosis submitted to in vitro fertilization-a pilot study. Gynecol Endocrinol 20 5 (2005) 284-288
30. Vlodavsky I., Friedmann Y., Elkin M., et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 5 (1999) 793-802
31. Drenkhahn M., Gescher D.M., Wolber E.M., et al. Expression of angiopoietin 1 and 2 in ectopic endometrium on the chicken chorioallantoic membrane. Fertil Steril 81 Suppl. 1 (2004) 869-875
32. Dempsey L.A., Brumn G.J., and Platt J.L. Human heparanase, a potent regulator of cell matrix interactions. Trends Biochem Sci 25 8 (2000) 349-351
33. Parish C.R., Freeman C., and Hulett M.D. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 1471 3 (2001) M99-M108
34. Dong J., Kukula A.K., Toyoshima M., et al. Genomic organization and chromosome localization of the newly identified human heparanase gene. Gene 253 (2000) 171-178
35. Vlodavsky I., Fuks Z., Ishai-Michaeli R., et al. Extracellular matrix-resident basic fibroblast growth factor: implication for the control of angiogenesis. J Cell Biochem 45 2 (1991) 167-176
36. Halme J., Hammond M.G., Hulka J.F., et al. Retrograde menstruation in healthy women and in patients with endometriosis. Obstet Gynecol 64 (1984) 151-154
37. Malsonpiewe P.C., Suri C., Jones P.F., et al. Angiopoietin-2, a natural antagonist for tie-2 that disrupts in vivo angiogenesis. Science 277 5322 (1997) 55-60
38. Holash J., Maisonpieire P.C., Compton D., et al. Vessel cooption regression and growth in tumors mediated by angiopoietin and VEGF. Science 284 5422 (1999) 1994-1998
39. Nisolle M., and Donnez J. Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities. Fertil Steril 68 (1997) 585-596
40. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
41. Mclaren J., Prentice A., Charnock-Jones D.S., et al. Vascular endothelial growth factor concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod 11 1 (1996) 220-223
42. Donnez J., Smoes P., Gillerot S., et al. Vascular endothelial growth factor(VEGF) in endometriosis. Hum Reprod 13 6 (1998) 1686-1690
43. Mikami S., Ohashi K., Katsube K., et al. Coexpression of heparanase, basic fibroblast growth factor and vascular endothelial growth factor in human esophageal carcinomas. Pathol Int 54 8 (2004) 556-563
44. Joyce J.A., Freeman C., Meyer-Morse N., et al. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 24 25 (2005) 4037-4051
45. Khachigian L.M., and Parish C.R. Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies. Cardiovasc Drug Rev 22 1 (2004) 1-6
46. Mandriota S.J., and Pepper M.S. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res 83 8 (1998) 852-859
47. Vlodavsky I., Elkin M., Pappo O., et al. Mammalian heparanase as mediator of tumor metastasis and angiogenesis. Isr Med Assoc J 2 Suppl. (2000) 37-45
48. Vlodavsky I., Miao H.Q., Medalion B., et al. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev 15 2 (1996) 177-186
49. Elkin M., Ilan N., Ishai-Michaeli R., et al. Heparanase as mediator of angiogenesis: mode of action. FASEB J 15 9 (2001) 1661-1663
50. Stetler-Stevenson W.G. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103 9 (1999) 1237-1241